August 2023 Global Innovative Drug Report
Our August 2023 drug report offers an in-depth look into the pharmaceutical industry’s recent innovations, diving deep into individual drug analyses. Within, you’ll find details on each drug’s profile, R&D status, active patents, mechanisms of action, clinical trials, competitive dynamics, and more.
This report consists of four parts:
- August new drug approvals
- New drug analysis
- Global drugs under Expedited Review Pathway
- Analysis of selected ERP drugs
Report Overview
1.) August Drug Approvals
In August 2023, a total of nine drugs received global approval. This included three monoclonal antibodies, two bispecific antibodies, two small molecule drugs (SMDs), one RNA vaccine, and one aptamer drug conjugate.
![Patsnap Synpase First Approved Durgs in August Daiichirona Avacincaptad Pegol](png/august-drug-approvals-796x1024.png)
2.) New Drug Analysis
This report features in-depth analyses of five newly approved drugs, including a thorough examination of Avacincaptad pegol.
Avacincaptad pegol treats the severe eye condition known as geographic atrophy. It aims to delay vision deterioration by preventing the immune system from damaging eye cells.
![Patsnap Synpase New Drug Analysis Avacincaptad pegol geographic atrophy](png/avacincaptad-pegol-snapshot-rd-status%e2%80%afpatsnap-synapse--771x1024.png)
![Patsnap Synpase Avacincaptad pegol active patent & analysis & geographic atrophy](png/avacincaptad-pegol-active-patent-analysis%e2%80%afpatsnap-synapse--781x1024.png)
![Patsnap Synpase Avacincaptad pegol Analysis Continued](png/avacincaptad-pegol-analysis-continued%e2%80%afpatsnap-synapse--763x1024.png)
3.) Global Drugs Under Expedited Review Pathway
What’s more, 56 drugs were placed on ERP in August, including 35 orphan drug designations, nine with fast track status, four targeting rare pediatric diseases, three under breakthrough therapy designation, three with priority reviews, two receiving accelerated approvals, and one granted conditional marketing approval.
![Patsnap Synpase Global Drugs Under Expedited Review Pathway KB-707 BC-004](png/august-2023-global-drugs-subject-to-expedited-review%e2%80%afsynapse--797x1024.png)
4.) Analysis of Selected ERP Drugs
This report also highlights five ERP drugs for detailed analysis. Focusing on Savolitinib — a receptor tyrosine kinase inhibitor targeting the mesenchymal-epithelial transition factor (MET), here’s what we uncovered:
![Savolitinib Snapshot & R&D Status & Active Patent, PatSnap Synapse](png/savolitinib-snapshot-rd-status-active-patent%e2%80%afpatsnap-synapse--817x1024.png)
![Savolitinib Analysis, Patsnap Synapse](png/savolitinib-analysis%e2%80%afpatsnap-synapse--789x1024.png)
Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.
Patsnap Synapse Database: An Overview and Key Features
Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, and biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today and experience the benefits for yourself!
R&D Decision Makers
Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps decision makers to navigate and steer the direction of innovation with confidence.
Business Development Professionals
We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.
Pharmaceutical Analyst
Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.
Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact [email protected].
Your recommended content
-
Introducing Hiro, an AI assistant built for IP and R&D workflows
Category: AI advancements | Category: AI development | Category: AI-tools | Category: Article | Category: artificial intelligence
Tuesday, May 14, 2024
Powered by Patsnap’s industry-specific LLM, Hiro is designed to streamline IP and R&D workflows from ideation to product launch. With its robust AI capabilities, Hiro brings a new level of efficiency, precision, and security to tasks that were once time-consuming and labor-intensive.What sets Hiro apart is that it draws from our large language model that’s been trained on market-leading patent records, academic papers, and proprietary innovation data. This ensures we deliver more accurate and reliable results for every prompt.
-
Powering the Future of Electric Vehicles: The Battle for Battery Innovation and Patents
Category: Article | Category: battery technology | Category: electric vehicle | Category: EV | Category: lithium ion | Category: lithium ion battery | Category: NEV | Category: new energy vehicles
Monday, April 22, 2024
In the ever-evolving landscape of innovation, the electric vehicle (EV) industry stands as a beacon of technological transformation. As we explore the patents propelling the EV revolution, Apple's venture serves as a poignant example of the challenges even industry giants face in this competitive arena. Join us on a journey through the global patent landscape, where the quest for superior power solutions unfolds, and where the true pioneers of the EV revolution are making their mark.
-
The People vs. AI: Who Owns Ideas in the Era of Generative Artificial Intelligence?
Category: AI era | Category: AI-driven creativity | Category: AI-generated creations | Category: Article | Category: copyright and patent rights | Category: digital innovation | Category: innovation | Category: intellectual property law | Category: legal implications | Category: OpenAI Sora | Category: patent law | Category: Research Tag | Category: Sora | Category: text-to-video generative AI | Category: who owns AI
Monday, April 22, 2024
OpenAI’s Sora software, a text-to-video generative AI model, recently made headlines showing a series of 1-paragraph prompts and some high-quality footage generated based on those prompts. It is a rightfully impressive showing, but it’s still too early to identify how IP law will be disrupted by generative AI. This editorial delves into the multifaceted landscape of Sora's impact, offering insights into the future of innovation and ownership in the AI era.